Urine Test to Predict Response to BCG Bladder Cancer Treatment
Studies a urine test that may predict which bladder cancer patients respond to BCG therapy.
Plain-language title generated from the registry record
Registry title: Predicting BCG Response
Key facts
- Where
- Kyoto, JapanSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed intermediate or high-risk non-muscle invasive bladder cancer who are about to start BCG treatment in the bladder. A urine sample is collected to see who responds to BCG.
- Age
- 18 to 90 years
- Sex
- All sexes can join.
- Disease stage
- Urothelial bladder cancer of stage Ta, carcinoma in situ (CIS) or T1, diagnosed within 90 days before BCG, with intermediate or high-grade disease. No visible tumors left. No spread to lymph nodes or elsewhere in T1 disease. No cancer in the upper urinary tract.
- Earlier treatment
- Scheduled to start BCG in the bladder within 4 weeks of signing consent. No earlier BCG in the bladder. Visible tumors removed within 30 days before BCG. One dose of chemotherapy into the bladder right after surgery is allowed.
Main reasons for not taking part
- Earlier BCG treatment in the bladder
- Pure squamous cell cancer, adenocarcinoma or micropapillary parts in the tumor
- Known tuberculosis or taking oral glucocorticoids
- Active urinary infection, urinary retention or kidney or bladder stones
- Radical cystectomy, ureteral stents or nephrostomy tubes
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT04564781, who can take part
Where in Japan
- Kyoto UniversityKyoto, JapanContact: Yuki Kita, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Cedars-Sinai Medical Center
- Trial code
- NCT04564781
- Record updated
- 6 July 2026
- Original description
To date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a) require additional intravesical therapy or b) require cystectomy. A urine-based diagnostic that possesses the potential to accurately identify patients who will respond favorably to intravesical BCG is desperately needed.Read full original descriptionShow less
A Novel Multiplex Immunoassay for Predicting Intravesical BCG Response in Patients With Intermediate or High-risk Non-muscle Invasive Bladder Cancer
To date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a) require additional intravesical therapy or b) require cystectomy. A urine-based diagnostic that possesses the potential to accurately identify patients who will respond favorably to intravesical BCG is desperately needed.
Inclusion: Age 18 years or older; Patients must have histologically proven Ta, carcinoma in situ (CIS) or T1 stage urothelial cell carcinoma of the bladder diagnosed within 90 days prior to scheduled BCG; Patients must have had all grossly visible papillary tumors removed within 30 days prior to scheduled BCG or cystoscopy confirming no grossly visible papillary tumors within 30 days prior to scheduled BCG; Patients with T1 disease must have cross-sectional imaging of abdomen/pelvis demonstrating no evidence of nodal involvement or metastatic disease (CT scan or MRI scan) within 90 days prior to scheduled BCG; Patients must have intermediate or high-grade bladder cancer as defined by 2004 WHO/ISUP classification; Patients must not have pure squamous cell carcinoma or adenocarcinoma; Patients' disease must not have micropapillary components; Patients must have no evidence of upper tract (renal pelvis or ureters) cancer confirmed by one of the following tests performed within 90 days prior to BCG: CT urogram, intravenous pyelogram, MR urogram, or retrograde pyelograms; No other prior non-bladder malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years. Patients with localized prostate cancer who are being followed by an active surveillance program are also eligible; Participants may be treated with immediate post-operative intravesical instillation of a chemotherapeutic agent; Scheduled to undergo intravesical BCG therapy within 4 weeks of signing consent; Willing and able to give written informed consent (see Appendix 1); Willing to provide voided urine sample.
Exclusion: Previous intravesical BCG therapy; Patients must not be planning to receive concomitant biologic therapy, hormonal therapy, chemotherapy, surgery, or other cancer therapy while on study; Have recent genitourinary instrumentation (within 7 days prior to signing consent); Patients must not have known history of tuberculosis; Have incomplete TUR, i.e., visible residual disease; Have a known active urinary tract infection or urinary retention; Have active stone disease (renal or bladder) or renal insufficiency (creatinine >2.0 mg/dL) - Serum creatinine value can be up to 2 years before consent, otherwise repeat; Patients must not be taking oral glucocorticoids at the time of registration; Have had radical cystectomy; Have ureteral stents, nephrostomy tubes or bowel interposition; Be unable or unwilling to complete BCG induction and maintenance regimen.